Maryanne Demasi, reports

Maryanne Demasi, reports

Share this post

Maryanne Demasi, reports
Maryanne Demasi, reports
FDA branded ‘shameful’ over infant meningococcal vaccine approval

FDA branded ‘shameful’ over infant meningococcal vaccine approval

Regulator under fire for expanding infant use of meningococcal vaccine—1 in 20 reported suffering a serious adverse event in the study period.

Maryanne Demasi, PhD's avatar
Maryanne Demasi, PhD
Jun 08, 2025
∙ Paid
138

Share this post

Maryanne Demasi, reports
Maryanne Demasi, reports
FDA branded ‘shameful’ over infant meningococcal vaccine approval
13
29
Share

“It’s shameful,” said attorney Aaron Siri of Siri & Glimstad LLP, criticising the FDA’s decision to expand use of the meningococcal vaccine MenQuadfi to infants as young as six weeks.

Previously licensed for children over two, the vaccine is now approved for babies aged 6 weeks to 23 months, based on trials in which infants received up to four doses.

Siri, who has represented families affected by vaccine injury, says the move reflects a broader pattern of weak oversight—where flawed trial designs and circular assumptions are used to justify approvals despite serious safety concerns.

Aaron Siri, an attorney at Siri & Glimstad LLP

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Maryanne Demasi
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share